RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
5-AMINO-1MQ is a small molecule studied for its ability to inhibit nicotinamide N-methyltransferase, an enzyme commonly shortened to NNMT. Researchers have investigated this compound in laboratory models involving fat-cell metabolism, obesity-related metabolic changes, and aging muscle. The studies discussed here provide evidence about biological mechanisms in cells and animals. They do not establish that 5-AMINO-1MQ is safe or effective for weight management, muscle recovery, or any other use in people. [1,3–5]
WHAT IS 5-AMINO-1MQ?
5-AMINO-1MQ stands for 5-amino-1-methylquinolinium. It is a small chemical compound rather than a peptide. Researchers use it to investigate what happens when NNMT activity is reduced. A 2018 study examined its activity in cultured fat cells and in mice with diet-induced obesity. [1]
WHY DO RESEARCHERS STUDY NNMT?
NNMT changes how cells process nicotinamide, a form of vitamin B3. It transfers a methyl group from a molecule called SAM to nicotinamide, producing 1-methylnicotinamide. This connects NNMT activity with pathways involved in cellular metabolism, including those associated with NAD+, a molecule involved in energy-related reactions. [1,2]
An influential 2014 study reduced NNMT expression in mice using a gene-silencing approach. The researchers observed protection against diet-induced obesity and changes in fat-tissue metabolism. This helped establish interest in NNMT as a research target. However, that experiment did not test 5-AMINO-1MQ, so its findings should not be described as direct evidence for this particular compound. [2]
WHAT DID THE EARLY CELL AND MOUSE STUDIES FIND?
In the 2018 study, 5-AMINO-1MQ reduced an NNMT reaction product and increased NAD+ and SAM in cultured fat cells. The investigators also reported reduced fat formation in their cell model. In a short experiment involving mice with diet-induced obesity, the compound reduced body weight and white fat mass without a measured reduction in food intake. These findings describe specific experimental conditions, not established outcomes in people. [1]
WHAT DID LATER METABOLIC RESEARCH ADD?
A 2024 study followed mice with diet-induced obesity over 28 days. Compared with controls, mice receiving 5-AMINO-1MQ had smaller increases in body weight and fat mass, alongside improvements in measures of glucose tolerance and insulin sensitivity. The investigators also reported less fat accumulation in the liver. [3]
The distinction between losing weight and gaining less weight matters. This study reported limited weight and fat gain during the experiment. Its results should not be rewritten as proof of sustained weight loss or successful treatment of a human metabolic condition. [3]
WHAT HAS BEEN STUDIED IN AGING MUSCLE?
A 2019 study examined NNMT inhibition in muscle-cell experiments and an injury model involving aged mice. The researchers reported increased muscle stem-cell activity and improved regeneration in aged skeletal muscle. This work investigated repair processes under controlled experimental conditions; it did not establish a recovery benefit in people. [4]
A separate 2024 study examined 5-AMINO-1MQ, exercise, and their combination in aged mice over eight weeks. The investigators found improvements in grip strength, with a larger response when the compound and exercise were combined. However, another measure of muscle function, peak plantarflexor torque, did not significantly change. The mixed results show why a finding from one strength test should not be described as an improvement in every aspect of muscle performance. [5]
HOW MUCH OF THIS EVIDENCE COMES FROM HUMAN STUDIES?
The direct compound studies summarized here used laboratory cells or animals. They were not clinical trials establishing benefits in people. Animal experiments can help identify mechanisms and questions for further investigation, but they cannot determine human effectiveness, appropriate exposure, or long-term safety. [1,3–5]
Similarly, research involving NNMT as a biological target does not automatically validate every compound that inhibits it. Evidence must be evaluated for the specific substance, experimental model, and outcome being discussed.
WHAT REMAINS UNCERTAIN?
Questions remain about how reproducible these findings are across research groups and experimental settings, how effects change with longer observation, and which biological changes are directly responsible for the measured results. A change in a laboratory marker also needs to be distinguished from a meaningful change in function.
Published experiments do not establish the identity, purity, stability, or performance of a separately supplied research material. Those questions require documentation and testing specific to that material. The studies reviewed here support continued investigation of NNMT biology; they do not validate consumer use or claims about products sold on this website.
REFERENCES
[1] Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141–152.
https://doi.org/10.1016/j.bcp.2017.11.007
[2] Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508:258–262.
https://doi.org/10.1038/nature13198
[3] Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism. 2024;26:5272–5282.
https://doi.org/10.1111/dom.15879
[4] Neelakantan H, Brightwell CR, Graber TG, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019;163:481–492.
https://doi.org/10.1016/j.bcp.2019.02.008
[5] Dimet-Wiley AL, Latham CM, Brightwell CR, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Scientific Reports. 2024;14:15554.